Clinical Trial Update: A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cabozantinib as maintenance therapy to prevent progression or recurrence in high-risk pediatric solid tumors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma
• Sarcoma

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Nationwide Children's Hospital | Conditions: Neuroblastoma, Sarcoma | Phase 2 | Status: RECRUITING